Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B Gottlieb

Showing results (461-470 of 523) with videos related to

Pageof 53
Sort By:
The British Journal of Dermatology|September 7, 2018
Benefit-risk profile of tofacitinib in patients with moderate-to-severe chronic plaque psoriasis: pooled analysis across six clinical trialsB E Strober, A B Gottlieb, P C M van de Kerkhof, et al.
American Journal of Infection Control|June 25, 2026
Qualitative analyses of contributing factors to central line-associated bloodstream infections and catheter-associated urinary tract infections during the COVID-19 pandemicJessica Howard-Anderson, Victoria R Dotto, Lindsey B Gottlieb, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|March 5, 2014
A comparison of the malignancy incidence among patients with psoriatic arthritis and patients with rheumatoid arthritis in a large US cohortRachael L Gross, Julie S Schwartzman-Morris, Michael Krathen, et al.
Dermatology and Therapy|January 22, 2025
Long-Term Safety of Ixekizumab Treatment in Patients with Psoriasis, Psoriatic Arthritis, or Axial Spondyloarthritis: a Post Hoc Analysis of Cerebro-Cardiovascular EventsMark Lebwohl, Atul Deodhar, Sergio Schwartzman, et al.
The Journal of Rheumatology|January 15, 2023
Safety of Guselkumab With and Without Prior Tumor Necrosis Factor Inhibitor Treatment: Pooled Results Across 4 Studies in Patients With Psoriatic ArthritisProton Rahman, Wolf-Henning Boehncke, Philip J Mease, et al.
The British Journal of Dermatology|July 1, 2015
Downmodulation of key inflammatory cell markers with a topical Janus kinase 1/2 inhibitorN Punwani, T Burn, P Scherle, et al.
Arthritis Research & Therapy|February 12, 2024
Long-term safety of Ixekizumab in adults with psoriasis, psoriatic arthritis, or axial spondyloarthritis: a post-hoc analysis of final safety data from 25 randomized clinical trialsAtul Deodhar, Andrew Blauvelt, Mark Lebwohl, et al.
JAMA Dermatology|January 24, 2024
Patient-Reported Outcome Measures for Health-Related Quality of Life in Patients With Psoriasis: A Systematic ReviewLourdes M Pérez-Chada, Zachary H Hopkins, Deepak M W Balak, et al.
JAMA Dermatology|July 9, 2025
Ixekizumab and Malignant Neoplasms: A Pooled Analysis of Data From 25 Randomized Clinical TrialsJoseph F Merola, Kim A Papp, Atul Deodhar, et al.
Journal of the American Academy of Dermatology|October 16, 2013
Research gaps in psoriasis: opportunities for future studiesCaitriona Ryan, Neil J Korman, Joel M Gelfand, et al.
Pageof 53

Showing results (461-470 of 523) with videos related to

Sort By:
Pageof 53
The British Journal of Dermatology|September 7, 2018
Benefit-risk profile of tofacitinib in patients with moderate-to-severe chronic plaque psoriasis: pooled analysis across six clinical trialsB E Strober, A B Gottlieb, P C M van de Kerkhof, et al.
American Journal of Infection Control|June 25, 2026
Qualitative analyses of contributing factors to central line-associated bloodstream infections and catheter-associated urinary tract infections during the COVID-19 pandemicJessica Howard-Anderson, Victoria R Dotto, Lindsey B Gottlieb, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|March 5, 2014
A comparison of the malignancy incidence among patients with psoriatic arthritis and patients with rheumatoid arthritis in a large US cohortRachael L Gross, Julie S Schwartzman-Morris, Michael Krathen, et al.
Dermatology and Therapy|January 22, 2025
Long-Term Safety of Ixekizumab Treatment in Patients with Psoriasis, Psoriatic Arthritis, or Axial Spondyloarthritis: a Post Hoc Analysis of Cerebro-Cardiovascular EventsMark Lebwohl, Atul Deodhar, Sergio Schwartzman, et al.
The Journal of Rheumatology|January 15, 2023
Safety of Guselkumab With and Without Prior Tumor Necrosis Factor Inhibitor Treatment: Pooled Results Across 4 Studies in Patients With Psoriatic ArthritisProton Rahman, Wolf-Henning Boehncke, Philip J Mease, et al.
The British Journal of Dermatology|July 1, 2015
Downmodulation of key inflammatory cell markers with a topical Janus kinase 1/2 inhibitorN Punwani, T Burn, P Scherle, et al.
Arthritis Research & Therapy|February 12, 2024
Long-term safety of Ixekizumab in adults with psoriasis, psoriatic arthritis, or axial spondyloarthritis: a post-hoc analysis of final safety data from 25 randomized clinical trialsAtul Deodhar, Andrew Blauvelt, Mark Lebwohl, et al.
JAMA Dermatology|January 24, 2024
Patient-Reported Outcome Measures for Health-Related Quality of Life in Patients With Psoriasis: A Systematic ReviewLourdes M Pérez-Chada, Zachary H Hopkins, Deepak M W Balak, et al.
JAMA Dermatology|July 9, 2025
Ixekizumab and Malignant Neoplasms: A Pooled Analysis of Data From 25 Randomized Clinical TrialsJoseph F Merola, Kim A Papp, Atul Deodhar, et al.
Journal of the American Academy of Dermatology|October 16, 2013
Research gaps in psoriasis: opportunities for future studiesCaitriona Ryan, Neil J Korman, Joel M Gelfand, et al.
Pageof 53